文献速递其他结缔组织病

幼年系统性硬化症胃肠道影响与UCLA GIT 2.0量表性能评估

Gastrointestinal Impact and Tool Performance in Juvenile Systemic Sclerosis Using the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract, Version 2.0 Assessment.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-02-11

该研究纳入51例幼年起病系统性硬化症(jSSc)患者,采用UCLA GIT 2.0患者报告结局工具评估胃肠道表现并检验其效度与反应性。患者平均总分为0.30,提示轻度胃肠道负担,腹胀和反流是最常受累领域;总分及各亚量表与SHAQ-GI-VAS和SHAQ-DIS-VAS呈中至强显著相关,支持聚合效度。22例配对数据中平均总分改善0.11分(P=0.039),55%至少一个领域达到临床重要改善,提示初步反应性。

要点

  • jSSc患者UCLA GIT 2.0平均总分为0.30,提示轻度胃肠道症状负担。
  • 腹胀和反流是最常受累领域,各见于超过70%的患者。
  • 22例配对数据中总分平均改善0.11分(P=0.039),55%至少一个领域达临床重要改善。

核心结论

  • UCLA GIT 2.0能捕捉jSSc患者胃肠道症状的频率和严重程度,并显示出可接受的效度和对变化的敏感性。
  • 该工具虽为成人开发,但似乎适合在研究 and 临床环境中监测儿童SSc患者的胃肠道结局。

研究设计与样本

  • 纳入来自美国儿童起病硬皮病国家登记处、完成UCLA GIT 2.0的jSSc患者。
  • 总结人口学与临床数据、各领域及UCLA GIT 2.0总分。
  • 通过与SHAQ-GI-VAS和SHAQ-DIS-VAS的Spearman相关性评估聚合效度。
  • 在1年后有配对UCLA GIT 2.0评估的患者中探索反应性。

主要发现

  • 共51例jSSc患者,起病平均年龄9.8岁,平均病程4.4年,UCLA GIT 2.0平均总分为0.30,提示轻度胃肠道负担。
  • 腹胀和反流是最常受累领域,各见于超过70%的患者。
  • UCLA GIT 2.0总分及各亚量表与SHAQ-GI-VAS和SHAQ-DIS-VAS呈中至强显著相关,支持聚合效度。
  • 22例配对数据中,UCLA GIT 2.0平均总分改善0.11分(P=0.039),55%的患者至少一个领域达到临床重要改善,提示初步反应性。

关键数值与推荐

  • UCLA GIT 2.0平均总分为0.30,提示轻度胃肠道负担。
  • 腹胀和反流各见于超过70%的患者。
  • 22例配对数据中平均总分改善0.11分(P=0.039),55%至少一个领域达到临床重要改善。

临床怎么用

  • 作者认为UCLA GIT 2.0似乎适合在研究 and 临床环境中监测儿童SSc患者的胃肠道结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study is to characterize gastrointestinal (GI) manifestations in patients with juvenile-onset systemic sclerosis (jSSc) using the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract, version 2.0 (UCLA GIT 2.0) patient-reported outcome (PRO) instrument, and to evaluate its validity and responsiveness in this population. METHODS: Patients with jSSc from the National Registry for Childhood Onset Scleroderma who completed the UCLA GIT 2.0 were included. Demographic and clinical data, domain, and total UCLA GIT 2.0 scores were summarized. Convergent validity was assessed by Spearman correlations with the Scleroderma Health Assessment Questionnaire GI visual analog scale (SHAQ-GI-VAS) and the SHAQ Disease VAS (SHAQ-DIS-VAS). Responsiveness was explored in patients with paired UCLA GIT 2.0 assessments one year later. RESULTS: Fifty-one patients with jSSc (mean age at onset, 9.8 years; mean disease duration, 4.4 years) had a mean UCLA GIT 2.0 total score of 0.30, indicating a mild GI burden. Distension and bloating and reflux were the most affected domains, each reported in more than 70% of patients. Total and subscale UCLA GIT 2.0 scores showed moderate to strong significant correlations with the SHAQ-GI-VAS and SHAQ-DIS-VAS, supporting convergent validity. Among 22 patients with paired data, the mean total UCLA GIT 2.0 improved by 0.11 points (P = 0.039), and 55% of these patients achieved a clinically important improvement in at least one domain, indicating preliminary responsiveness. CONCLUSION: The UCLA GIT 2.0 captures the frequency and severity of GI symptoms in patients with jSSc and demonstrates acceptable validity and sensitivity to change. Although developed for adults, the instrument appears suitable for monitoring GI outcomes in pediatric patients with SSc in both research and clinical settings.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Stefancic S, Robinson A, Havrilla HJ, et al. Gastrointestinal Impact and Tool Performance in Juvenile Systemic Sclerosis Using the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract, Version 2.0 Assessment. Arthritis Care Res (Hoboken). 2026. PMID: 40888178. doi:10.1002/acr.25643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。